What is the earliest age at which the MenQuadfi (quadrivalent MenACWY) vaccine can be administered?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 6, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

MenQuadfi Earliest Age of Administration

MenQuadfi (MenACWY-TT) can be administered as early as 6 weeks of age 1.

FDA-Approved Dosing by Age

According to the FDA prescribing information, MenQuadfi is approved for individuals 6 weeks of age and older, with the following primary vaccination schedules 1:

Infants and Young Children

  • 6 weeks to <2 months: First dose may be given as early as 6 weeks when starting the 4-dose series (at 2,4,6, and 12-18 months)
  • 2 months: Standard 4-dose series at 2,4,6, and 12-18 months of age
  • 6-11 months: 2-dose series with second dose in the second year of life, at least 3 months after first dose
  • 12-23 months: 2-dose series with second dose at least 3 months after first dose

Children and Adults

  • ≥2 years: Single dose for primary vaccination

ACIP Guideline Context

The 2020 ACIP guidelines confirm that MenACWY-TT (MenQuadfi) is licensed for persons aged ≥2 years for routine use 2. However, the FDA label extends approval down to 6 weeks of age, which represents the absolute earliest age for administration 1.

Important Clinical Considerations

For outbreak situations or high-risk populations, the vaccine can be initiated as early as 6 weeks, though ACIP guidelines primarily focus on routine recommendations starting at 2 months for infants at increased risk 2.

Key distinction from other MenACWY vaccines:

  • MenACWY-D (Menactra): Licensed ≥9 months
  • MenACWY-CRM (Menveo): Licensed ≥2 months
  • MenACWY-TT (MenQuadfi): Licensed ≥6 weeks (earliest option)

Safety Data

Recent Phase III data support the safety profile of MenQuadfi in infants as young as 6 weeks when administered concomitantly with routine pediatric vaccines 3. The vaccine was well-tolerated with comparable safety profiles to other licensed meningococcal vaccines in this age group.

Bottom line: While routine ACIP recommendations typically begin at 2 months for at-risk infants, the FDA-approved earliest age for MenQuadfi administration is 6 weeks, making it the only MenACWY vaccine licensed for use this early in life.

Related Questions

For a healthy 16‑year‑old male with no prior meningococcal vaccination, is a two‑dose meningococcal vaccine schedule recommended?
For a 16-year-old male, what is the recommended interval between the quadrivalent meningococcal (MenACWY) booster dose and the serogroup B meningococcal (MenB) doses?
Is it safe to administer Nimenrix (meningococcal ACWY conjugate vaccine) now to a patient who received a tetanus-containing vaccine six months ago?
How many doses of MenACWY (Meningococcal Conjugate) vaccine does a 16-year-old need?
What meningococcal vaccination schedule is recommended for a 16‑year‑old male who has not received any meningococcal vaccine yet?
What is the recommended urgent workup and management for a patient with right‑sided upper extremity numbness and tingling in the C8–T1 distribution (pinky and fourth finger) and right‑sided lower extremity numbness and tingling from the buttock to the foot?
What is the echocardiographic finding of posterior mitral valve prolapse?
How is a gentle eyelid massage performed?
What is the recommended protocol for tapering clonidine and initiating prazosin (alpha‑1 blocker) dosing, including titration schedule and monitoring?
What are the FDA‑approved infusion therapies for dementia (Alzheimer’s disease)?
In a 30-year-old Black male (6'5", 320 lb) with hypertension on amlodipine and GLP‑1 therapy, who has a positive ANA (1:160 speckled), markedly elevated anti‑U1‑RNP, negative anti‑centromere, anti‑Scl‑70, anti‑Sm, anti‑SSA/SSB, and anti‑dsDNA, normal complement C3/C4, mildly elevated CK (371–527 U/L), low‑normal ESR (2–18 mm/h), normal renal and liver function, and an upcoming EMG, what is the most likely diagnosis (inflammatory myositis associated with mixed connective‑tissue disease versus necrotizing autoimmune myopathy), is a muscle biopsy required, and how serious is the condition?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.